Richard Cunningham is the CEO & Director at Tyme Technologies Inc.
As the CEO & Director of Tyme Technologies Inc, the total compensation of Mr Cunningham at Tyme Technologies Inc is $355,968. There are 6 executives at Tyme Technologies Inc getting paid more, with James Biehl having the highest compensation of $1,500,980.
Mr Cunningham is 50, he's been the CEO & Director of Tyme Technologies Inc since . There are 15 older and 3 younger executives at Tyme Technologies Inc. The oldest executive at Tyme Technologies Inc is Gerald Sokol, 77, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O TYME TECHNOLOGIES, INC., 1 PLUCKEMIN WAY - SUITE 103, BEDMINSTER, NJ, 07921.
Over the last 7 years, insiders at Tyme Technologies Inc have traded over $11,656,990 worth of Tyme Technologies Inc stock and bought 384,831 units worth $412,502 . The most active insiders traders include Steve Hoffman, Michael Demurjian, eDouglas A Michels. On average, Tyme Technologies Inc executives and independent directors trade stock every 8 days with the average trade being worth of $15,104. The most recent stock trade was executed by Michael Demurjian on 6 September 2022, trading 160,000 units of TYME stock currently worth $40,000.
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.
With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.
Tyme Technologies Inc executives and other stock owners filed with the SEC include: